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related reactivity similar to that shown in
cytotoxicity assays the subject of much criticism at
that time.
The acceptance of the assay was not helped by
the fact that three assays were identified
(haemocytometer, tube and microplate) which not
only revealed different patterns of reactivity in
respect of correlation with the course of disease but
also in the nature of responsive cells and the
mechanism of reactivity. Each required a high level
of manual dexterity. The validity of the assay has,
however, been confirmed subsequently in elegant
studies using model antigens in both animal and
human systems (particularly by Powell and
associates) and this test should certainly rank with
the leukocyte migration inhibition assay with which
it has some similarities as a measure of immune
function.
This volume brings together the collected
experience of the several groups that have
successfully used LAI in its various forms and
identifies the methodological advances, such as
image analysis, and the difficulties of the test.
Large sections of the work deal with the
mechanisms of the different assays. Its aim is to
provide easy access to the information now
available in this area as well as a thorough
description of the technical aspects of the tests. To
be fair, much of the information has already been
published in the Cancer Research Monograph
reporting the 1978 Buffalo workshop on this assay.
Those familiar with the area will find little new
data on LAI (except in the paper by Thomson) and
a consideration of the role in rheumatoid arthritis.
The papers presented here largely retread well-worn
ground. It is significant that the experience of a
number of groups with less convincing data on the
applicability of LAI to investigations of immune
reactivity in malignant disease are not only missing
but not even mentioned!
Those committed to the use of LAI will find here
a useful compendium of the work of others in the
f'ield. As a review of the state of the art it succeeds
admirably. A critical document of the position of
LAI in cancer diagnosis it is not. If you have £30
to spend, keep it in your pocket and consult Cancer
Research, 39, 551-662 (1979). One may ask what
purpose a book like this, at such a price, has, given
the economic constraints now being placed on
library budgets and cancer research in general.
B.M. Vose,
Immunology Section,
Biosciences I,
ICI Pharmaceuticals Division,
Alderly Park, Cheshire.
Human Cancer Markers (Eds. S. SELL. and B.
WAHREN). Chichester. John Wiley & Sons Ltd, 428
pp, 1982, £42.95
The interset in cancer markers continues both in
the search for new markers as well as the growing
use of those markers that have passed from the
preliminary stage to commercial production. The
anchor topics such as markers in breast, bowel and
lung cancer each receive a chapter in this well
constructed volume. The authors explore and
explain the use and limitations of the markers in
current use in many hospitals, carcinoembryonic
antigen, alpha fetoprotein and a variety of
hormones that can identify tumours of the
endocrine system, as well as those tumours where
there is an inappropriate production of hormones.
The book, which is a companion to Dr. Sell's
Cancer Markers (Humana Press, Clifton, N.J. 1980)
is presented in series of 15 site-orientated chapters,
and a general overview of monoclonal antibodies.
The authors vary according to the chapters. A
personal viewpoint is expressed in several chapters
by well known contributors to their area of
research, S. Sell on the liver, J. Hobbs on the
pancreas, M. Seppala on the gynaecological cancers
to name a few, others write in pairs T.M.
Edgington teams with R.M. Nakamura on breast
cancer, B. Wahren (the co-editor) with P. Perlmann
on bladder cancer and so down through a list that
takes in skin, melanoma and central nervous
system; why it took 8 authors to write 9 pages
about prostatic cancer is unclear, they are a
veritable doctrine of doctors. I found the book
helpful and filled with a lot of good information
which with some cross-referencing provides an
appraisal of the state of the art in 1982. However,
as there has been a flood of tumour marker books
and conference reports on the market recently an
element of "deja vu" crept in from time to time as
I read some sections. Alas! This is the problem;
when so many publishing houses are in production,
the better books (and this is one) often get off to a
bad start with the readers fatigued by all that has
gone before. Nevertheless this book stands out
above the run of the mill, as a cornerstone for
research and practice in the 1980's.
E.H. Cooper,
Unit for Cancer Research,
School of Medicine,
Leeds.